Innoviva EV/EBIT INVA
Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2015.
- Today, Nov 2, 2026
- 7.4×
- 10-year median
- 6.5×
- Against its 10-year history
- 65th
- percentile: 0 is its lowest day, 100 its highest
- 10-year range
- 1.9× to 21.2×
- Peer median
- 8.9×
Innoviva's EV/EBIT is 7.4× as of Nov 2, 2026.
That is above its ten-year median of 6.5×, higher than on 65% of days in the last ten years.
Over that time it ranged from 1.9× in Feb 2023 to 21.2× in Feb 2017.
The median for 10 large drugmakers of a similar size is 8.9×.
EV/EBIT over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 7.4× | 7.0× | 9.2× |
| 2025 | 7.2× | 5.9× | 8.3× |
| 2024 | 6.7× | 5.5× | 15.5× |
| 2023 | 15.1× | 1.9× | 15.3× |
| 2022 | 2.1× | 2.0× | 4.9× |
| 2021 | 4.3× | 3.7× | 4.8× |
| 2020 | 3.9× | 3.2× | 6.5× |
| 2019 | 6.2× | 4.9× | 10.3× |
| 2018 | 9.0× | 8.5× | 14.3× |
| 2017 | 12.5× | 11.4× | 21.2× |
| 2016 | 19.6× | 18.3× | 137× |
| 2015 | 123× | 109× | 123× |
Against its peers
Companies in Drug Manufacturers - General nearest Innoviva's size, closest first, today.
| Company | EV/EBIT |
|---|---|
| INVAInnoviva | 7.4× |
| PAHCPhibro Animal Health | 11.6× |
| PCRXPacira BioSciences | 7.6× |
| ANIPANI Pharmaceuticals | 10.2× |
| ANABAnaptysbio | n/m |
| OMEROmeros | n/m |
| AMPHAmphastar Pharmaceuticals | 12.9× |
| HRMYHarmony Biosciences | 7.3× |
| PBHPrestige Consumer Healthcare | 14.8× |
| NRIXNurix Therapeutics | 7.2× |
| ABUSArbutus Biopharma | 4.7× |
| Peer median | 8.9× |
Where Innoviva ranks
What the EV/EBIT tells you
What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.
Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.
More on Innoviva
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.